Three patients with indinavir-related urolithiasis;Drie patiënten met urolithiasis als bijwerking van behandeling met indinavir

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 33, 2007, Pages 1839-1845

  Brandenburg, J J I ^a   Hoepelman, I M ^b   Stopper, G ^b   Lock, M T W T ^b  

^a CENTRAL MILITARY HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; ZIDOVUDINE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CATHETERIZATION; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; EMERGENCY WARD; EXTRACORPOREAL LITHOTRIPSY; FEVER; FLANK PAIN; FOLLOW UP; HEMOPHILIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS PYELOGRAPHY; KIDNEY PELVIS; MALE; MINIMALLY INVASIVE SURGERY; PENIS GLANS; PERCUTANEOUS NEPHROLITHOTOMY; TREATMENT OUTCOME; ULTRASOUND; URETER; URINE ACIDIFICATION; UROGRAPHY; UROLITHIASIS;

ADULT; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; KIDNEY PELVIS; LITHOTRIPSY; MALE; MIDDLE AGED; NEPHROSTOMY, PERCUTANEOUS; TREATMENT OUTCOME; UROLITHIASIS;

EID: 34548645716     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Gentle DL, Stoller ML, Jarrett TW, Ward JF, Geib KS, Wood AF. Protease inhibitor-induced urolithiasis. Urology. 1997;50:508-11.
2. Wu DS, Stoller ML. Indinavir urolithiasis. Curr Opin Urol. 2000;10:557-61.
3. Borleffs JCC, Danner SA, Lange JMA, Everdingen JJE van. CBO-richtlijn 'Antiretrovirale behandeling in Nederland'. Ned Tijdschr Geneeskd. 2001;145:1585-9.
4. Salahuddin S, Buchholz N, Griffith G, Kok DJ. Indinavir: from crystal to stone [abstract]. In: Kok DJ, Romijn HC, Verhagen PCMS, Verkoelen CF, editors. Eurolithiasis. Maastricht: Shaker; 2001. p. 152-6.
5. Kohan AD, Armenakas NA, Fracchia JA. Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. J Urol. 1999;161:1765-8.
6. Hermieu JF, Prevot MH, Ravery V, Sauty L, Moulinier F, Delmas V, et al. Urolithiasis and the protease inhibitor indinavir. Eur Urol. 1999;35:239-41.
7. Reiter WJ, Schon-Pernerstorfer H, Dorfinger K, Hofbauer J, Marberger M. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol. 1999;161:1082-4.
8. Hug B, Naef M, Bucher HC, Sponagel L, Lehmann K, Battegay M. Treatment for human immunodeficiency virus with indinavir may cause relevant urological side-effects, effectively treatable with rehydration. BJU Int. 1999;84:610-4.
9. Saltel E, Angel JB, Futter NG, Walsh WG, O'Rourke K, Mahoney JE. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol. 2000;164:1895-7.
10. Brodie SB, Keller MJ, Ewenstein BM, Sax PE. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS. 1998;12:2433-7.
11. Indinavir sulfate [bijsluitertekst]. West Point: Merck&Co; 1996.
12. Dieleman JP, Sturkenboom MC, Jambroes M, Gyssens IC, Weverling GJ, Veen JH ten, et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. Athena Study Group. Arch Intern Med. 2002;162:1493-501.
13. Dieleman JP, Rossum AM van, Stricker BC, Sturkenboom MC, Groot R de, Telgt D, et al. Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. J Acquir Immune Defic Syndr. 2003;32:135-42.
14. Rossum AM van, Dieleman JP, Fraaij PL, Cransberg K, Hartwig NG, Gyssens IC, et al. Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1 infected children. AIDS. 2001;15:1745-7.
15. Jaarverslag 2004. Amsterdam: Stichting HIV monitoring; 2005. p. 13-6.
16. Nadler RB, Rubenstein JN, Eggenet SE, Loor MM, Smith ND. The etiology of urolithiasis in HIV infected patients. J Urol. 2003;169:475-7.
17. Salahuddin S, Hsu YS, Buchholz NP, Dieleman, JP, Gyssens IC, Kok DJ. Is indinavir crystalluria an indicator for indinavir stone formation? AIDS. 2001;15:1079-80.
18. Dieleman JP, Salahuddin S, Hsu YS, Burger DM, Gyssens IC, Sturkenboom MC, et al. Indinavir crystallization around the loop of Henle: experimental evidence. J Acquir Immune Defic Syndr. 2001;28:9-13.
19. Kopp JB, Miller KD, Mican JA, Feuerstein IM, Vaughan E, Baker C, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127:119-25.
20. Schwartz BF, Schenkman N, Armenakas NA, Stoller ML. Imaging characteristics of indinavir calculi. J Urol. 1999;161:1085-7.
21. Hermans BP, Materne R, Marot JC, Vandercam B, Beers BE van, Cangh PJ van. Indinavir calculi: diagnosis with magnetic resonance urography. Eur Urol. 2000;37:634-5.
22. Sutherland SE, Reigle MD, Seftel AD Resnick MI. Protease inhibitors and urolithiasis. J Urol. 1997;158:31-3.
23. Rich JD, Ramratnam B, Chiang M, Tashima KT. Management of indinavir associated nephrolithiasis. J Urol. 1997;158:2228.
24. Lerner LB, Cendron M, Rous SN. Nephrolithiasis from indinavir, a new human immunodeficiency virus drug. J Urol. 1998;159:2074.
25. Bruce RG, Munch LC, Hoven AD, Jerauld RS, Greenburg R, Porter WH, et al. Urolithiasis associated with the protease inhibitor indinavir. Urology. 1997;50:513-8.